Secondary Outcomes The secondary outcomes of the study are whether topical 0.15% ganciclovir will (1) reduce the incidence and severity of second eye involvement, (2) reduce the incidence and severity of subepithelial infiltrates, (3) reduce the secondary spread to family members, friends, classmates or co-workers (The virus is very stable at room temperature and can last for days on fomites, like towels, doorknobs, etc), (4) reduce the degree of bulbar conjunctival injection (redness of the eye, as determined by the Efron scale in the Appendix 2), (5) reduce ocular discomfort, and (6) be considered an effective treatment by the patient.